{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:31:22Z","timestamp":1769596282777,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"janssen pharmaceutical k.k."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction\/objectives<\/jats:title>\n                <jats:p>Since new consensus on polymyositis (PM) and dermatomyositis (DM) were released in Japan, an updated evidence on treatment landscape and PM\/DM burden was essential. This study evaluates treatment burden and overall treatment cost of PM\/DM-related inpatient and outpatient visits, treatments, and procedures\/patient\/year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This retrospective, observational study analyzed insurance claims from Japan Medical Data Center (JMDC) database. Patients with at least one PM\/DM diagnosis\/one dispensation of treatment between 1 January 2009 and 31 December 2019 were enrolled. Patient characteristics, treatment patterns and sequence, treatment choices, healthcare resource utilization (HCRU), and related costs were assessed. Chi-square test and linear regression model were used to assess impact of patient characteristics on treatment choice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients (836\/4,961) receiving a relevant treatment were analyzed. Heart disease (35%), interstitial lung disease (27%), and diabetes mellitus (26%) were frequently identified as comorbidities. Concomitant dispensation of immunosuppressants and systemic steroids was largely found in first and second line of treatment (LoT) while systemic steroids remained as single dominant treatment across all LoTs. HCRU was very low for inpatient visits (0.68 [1.43]) or rehabilitation (4.74 [14.57]). The mean (SD) number of inpatient visits decreased from first (1.23 [2.32]) to third year (0.11 [0.54]). Total mean (SD) healthcare cost per patients per year was \u00a5 3,815,912 (7,412,241), with overall drug dispensation compounding to 80% of total cost.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>High concomitant immunosuppressant and systemic steroid prescriptions in first LoT recommend early optimal treatment to manage PM\/DM. Although inpatient costs are low, outpatient dispensation costs increase overall economic burden.<\/jats:p>\n              <jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Japan faces treatment challenges in the prognosis of polymyositis (PM) and dermatomyositis (DM) and thus, we assessed the real-world treatment landscape, practice, patterns, and healthcare resource utilization as an evidence to support healthcare outcome improvement and treatment burden reduction.<\/jats:italic><jats:italic>\u2022 Systemic steroids were the dominant preferred choice of treatment, but it increases the overall cost of the treatment due to the resultant comorbidities considering possible side-effects promotion.<\/jats:italic><jats:italic>\u2022 Thus, an increased awareness towards the disease management among patients and medical doctors is required for better management goals based on this real-world practice evidence.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:sec>","DOI":"10.1007\/s10067-021-05939-6","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T09:02:54Z","timestamp":1634893374000},"page":"741-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-563X","authenticated-orcid":false,"given":"Celine","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia M.","family":"Stelmaszuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"5","key":"5939_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay AR, Goyal NA, Mozaffar T (2015) An overview of polymyositis and dermatomyositis. Muscle Nerve 51(5):638\u2013656","journal-title":"Muscle Nerve"},{"issue":"5","key":"5939_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","volume":"14","author":"IE Lundberg","year":"2018","unstructured":"Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14(5):269\u2013278","journal-title":"Nat Rev Rheumatol"},{"issue":"18","key":"5939_CR3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372(18):1734\u20131747","journal-title":"N Engl J Med"},{"issue":"1","key":"5939_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","volume":"11","author":"I Marie","year":"2011","unstructured":"Marie I, Mouthon L (2011) Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11(1):6\u201313","journal-title":"Autoimmun Rev"},{"key":"5939_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100018","volume":"2","author":"SH Yang","year":"2019","unstructured":"Yang SH, Chang C, Lian ZX (2019) Polymyositis and dermatomyositis - challenges in diagnosis and management. J Transl Autoimmun 2:100018. https:\/\/doi.org\/10.1016\/j.jtauto.2019.100018","journal-title":"J Transl Autoimmun"},{"issue":"3","key":"5939_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/14397595.2013.844308","volume":"24","author":"A Ohta","year":"2014","unstructured":"Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H (2014) Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod Rheumatol 24(3):477\u2013480","journal-title":"Mod Rheumatol"},{"issue":"4","key":"5939_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3109\/s10165-012-0733-7","volume":"23","author":"A Ohta","year":"2013","unstructured":"Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H (2013) Age at onset and gender distribution of systemic lupus erythematosus, polymyositis\/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol 23(4):759\u2013764","journal-title":"Mod Rheumatol"},{"key":"5939_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ncn3.12223","volume":"7","author":"H Kohsaka","year":"2019","unstructured":"Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T (2019) Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurol Clin Neurosci 7:3\u201321","journal-title":"Neurol Clin Neurosci"},{"issue":"9388","key":"5939_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971\u2013982","journal-title":"Lancet"},{"issue":"2","key":"5939_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Groupet (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5939_CR11","first-page":"1424","volume":"20","author":"L Christopher-Stine","year":"2020","unstructured":"Christopher-Stine L, Wan GJ, Kelly W, McGowan M, Bostic R, Reed ML (2020) Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. J Manag Care Spec Ph 20(11):1424\u20131433","journal-title":"J Manag Care Spec Ph"},{"issue":"1","key":"5939_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0028-3886.60386","volume":"58","author":"JMK Murthy","year":"2010","unstructured":"Murthy JMK (2010) Drug treatment of polymyositis and dermatomyositis. Neurol India 58(1):3\u20135","journal-title":"Neurol India"},{"issue":"5","key":"5939_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0019-5154.100479","volume":"57","author":"K Hunter","year":"2012","unstructured":"Hunter K, Lyon MG (2012) Evaluation and management of polymyositis. Indian J Dermatol 57(5):371\u2013374","journal-title":"Indian J Dermatol"},{"issue":"5","key":"5939_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","volume":"31","author":"DX Wang","year":"2012","unstructured":"Wang DX, Shu XM, Tian XL, Chen F, Zu N, Ma L, Wang GC (2012) Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review. Clin Rheumatol 31(5):801\u2013806","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5939_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/1346-8138.14604","volume":"46","author":"H Kohsaka","year":"2018","unstructured":"Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T (2018) Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J Dermatol 46(1):e1\u2013e18. https:\/\/doi.org\/10.1111\/1346-8138.14604","journal-title":"J Dermatol"},{"key":"5939_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12688\/f1000research.13585.1","volume":"7","author":"S Khosla","year":"2018","unstructured":"Khosla S, White R, Medina J, Ouwens M, Emmas C, Koder T, Male G, Leonard S (2018) Real world evidence (RWE) \u2013 a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res 7:111. https:\/\/doi.org\/10.12688\/f1000research.13585.1","journal-title":"F1000Res"},{"issue":"3","key":"5939_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3109\/14397595.2015.1091137","volume":"26","author":"H Tomimitsu","year":"2016","unstructured":"Tomimitsu H, Ohta A, Nagai M, Nishina M, Ishihara S, Kohsaka H (2016) Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis. Mod Rheumatol 26(3):398\u2013402","journal-title":"Mod Rheumatol"},{"key":"5939_CR18","unstructured":"Big Data (Medical Field) (2021) Japan Medical Data Center. https:\/\/www.jmdc.co.jp\/en\/bigdata. Accessed 2 July 2021"},{"issue":"8","key":"5939_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/pds.1082","volume":"14","author":"M Epstein","year":"2005","unstructured":"Epstein M (2005) Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 14(8):589\u2013595","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"5939_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20132194","journal-title":"JAMA"},{"issue":"8","key":"5939_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jval.2017.08.3018","volume":"20","author":"SV Wang","year":"2017","unstructured":"Wang SV, SchnUeeweiss S, Berger ML, Brown J, Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M, on behalf of the joint ISPE\u2010ISPOR Special Task Force on Real World Evidence in Health Care Decision Making (2017) Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies. Value Health 20(8):1009\u20131022","journal-title":"Value Health"},{"issue":"11","key":"5939_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130\u20131139","journal-title":"Med Care"},{"issue":"1","key":"5939_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44\u201347","journal-title":"Value Health"},{"issue":"12","key":"5939_CR24","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/rheumatology\/keq279","volume":"49","author":"I-J Chen","year":"2010","unstructured":"Chen I-J, Tsai W-P, Wu Y-JJ, Luo S-F, Ho H-H, Liou L-B, Chen J-Y, Kuo C-F, Chang H-C, Yang C-H, Yu K-H (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatol (Oxford) 49(12):2429\u20132437","journal-title":"Rheumatol (Oxford)"},{"key":"5939_CR25","unstructured":"Rare Disease Database (2018) Dermatomyositis. https:\/\/rarediseases.org\/rare-diseases\/dermatomyositis\/#:~:text=Polymyositis%20occurs%20most%20often%20in,over%20days%2C%20weeks%20or%20months. Accessed 2 Jun\u00a02021"},{"issue":"5","key":"5939_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.21037\/atm.2020.01.56","volume":"8","author":"SH Syue","year":"2020","unstructured":"Syue SH, Chang YH, Shih PJ, Lin CL, Yeh JJ, Kao CH (2020) Polymyositis\/dermatomyositis is a potential risk factor for acute respiratory failure: a pulmonary heart disease. Ann Transl Med 8(5):202. https:\/\/doi.org\/10.21037\/atm.2020.01.56","journal-title":"Ann Transl Med"},{"issue":"3","key":"5939_CR27","first-page":"461","volume":"55","author":"SK Rai","year":"2016","unstructured":"Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA (2016) Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatol (Oxford) 55(3):461\u2013469","journal-title":"Rheumatol (Oxford)"},{"key":"5939_CR28","unstructured":"Intractable Disease Measures (2009) Outline of intractable disease measures. https:\/\/www.mhlw.go.jp\/english\/wp\/wp-hw5\/dl\/23010223e.pdf. Accessed 2 Jun\u00a02021"},{"issue":"11","key":"5939_CR29","first-page":"686","volume":"35","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang GC, Ma L, Zu N (2012) Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 35(11):686\u2013691","journal-title":"Clin Cardiol"},{"issue":"6","key":"5939_CR30","doi-asserted-by":"publisher","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","volume":"9","author":"T Fujisawa","year":"2014","unstructured":"Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS One 9(6):e98824","journal-title":"PLoS One"},{"issue":"12","key":"5939_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/heartjnl-2019-315511","volume":"106","author":"LE Clarson","year":"2020","unstructured":"Clarson LE, Bajpai R, Whittle R, Belcher J, Sultan AA, Kwok CS, Welsh V, Mamas M, Mallen CD (2020) Interstitial lung disease is a risk factor for ischaemic heart disease and myocardial infarction. Heart 106(12):916\u2013922","journal-title":"Heart"},{"issue":"4","key":"5939_CR32","doi-asserted-by":"publisher","first-page":"e94128","DOI":"10.1371\/journal.pone.0094128","volume":"9","author":"X Lu","year":"2014","unstructured":"Lu X, Yang H, Shu X, Chen F, Zhang Y, Zhang S, Peng Q, Tian X, Wang G (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 9(4):e94128","journal-title":"PLoS One"},{"issue":"1","key":"5939_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1515\/folmed-2017-0003","volume":"59","author":"LA Dourmishev","year":"2017","unstructured":"Dourmishev LA (2017) Inflammatory myopathies with cutaneous involvement: from diagnosis to therapy. Folia Med (Plovdiv) 59(1):7\u201313","journal-title":"Folia Med (Plovdiv)"},{"issue":"5","key":"5939_CR34","first-page":"880","volume":"34","author":"S Tansley","year":"2016","unstructured":"Tansley S, Shaddick G, Christopher-Stine L, Sharp C, Dourmishev L, Maurer B, Chinoy H, McHugh N (2016) Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. Clin Exp Rheumatol 34(5):880\u2013884","journal-title":"Clin Exp Rheumatol"},{"key":"5939_CR35","first-page":"2855","volume":"27","author":"KA Qushmaq","year":"2000","unstructured":"Qushmaq KA, Chalmers A, Esdaile JM (2000) Cyclosporin A in the treatment of refractory adult polymyositis\/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 27:2855\u20132859","journal-title":"J Rheumatol"},{"issue":"7","key":"5939_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3111\/13696998.2016.1151433","volume":"19","author":"JB Rice","year":"2016","unstructured":"Rice JB, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M (2016) Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. J Med Econ 19(7):649\u2013654","journal-title":"J Med Econ"},{"key":"5939_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1046\/j.1525-1497.1999.00324.x","volume":"14","author":"MT Donohoe","year":"1999","unstructured":"Donohoe MT, Kravitz RL, Wheeler DB, Chandra R, Chen A, Humphries N (1999) Reasons for outpatient referrals from generalists to specialists. J Gen Intern Med 14:281\u2013286","journal-title":"J Gen Intern Med"},{"issue":"4","key":"5939_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jbspin.2020.03.002","volume":"87","author":"P Ungprasert","year":"2020","unstructured":"Ungprasert P, Wannarong T, Cheungpasitporn W, Wijarnpreecha K, Thongprayoon C, Kroner PT (2020) Inpatient burden and resource utilization of polymyositis and dermatomyositis: A 10-year Study of National Inpatient Sample. Joint Bone Spine 87(4):327\u2013330","journal-title":"Joint Bone Spine"},{"issue":"3","key":"5939_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-019-04248-1","volume":"39","author":"DP Misra","year":"2019","unstructured":"Misra DP, Agarwal V (2019) Real-world evidence in rheumatic diseases: relevance and lessons learnt. Rheumatol Int 39(3):403\u2013416","journal-title":"Rheumatol Int"},{"issue":"9453","key":"5939_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM (2005) External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d Lance 365(9453):82\u201393","journal-title":"Lance"},{"issue":"2","key":"5939_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1370\/afm.516","volume":"4","author":"M Fortin","year":"2006","unstructured":"Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L (2006) Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 4(2):104\u2013108","journal-title":"Ann Fam Med"}],"updated-by":[{"DOI":"10.1007\/s10067-022-06242-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05939-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:08:21Z","timestamp":1655186901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05939-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5939"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05939-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-022-06242-8","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-022-06242-8","URL":"https:\/\/doi.org\/10.1007\/s10067-022-06242-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Rheumatology Research Concept Approval Team in accordance with Japanese ethical and legal guidelines. JMDC data is anonymized electronic health insurance claims data which is created and aggregated under the compliance Personal Information Protection Law Article 2, Paragraph 9. Using this data as secondary research analysis does not require informed consent as per the Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor, and Welfare. This study was designed, implemented and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology, and with the ethical principles laid down in the Declaration of Helsinki. Reporting of claims data was based on International Society for Pharmacoeconomics and Outcomes Research and STORBE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CM and YI were employees of Janssen Pharmaceutical K.K. and NMS was an employee of Parexel at the time the study was conducted. NMS received payment for the data analysis, quality control, and data management.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}